For instance, the suppression of NRF2 expression reverses GPX4 inhibitor-induced ferroptosis resistance in head and neck tumors [51] and artesunate-induced ferroptosis resistance in cisplatin-resistant head and neck cancer cells [52]. Here, GPX4 is linked to head and neck cancer.